CA3081582A1 - Method of treatment of gastrointestinal diseases with tradipitant - Google Patents

Method of treatment of gastrointestinal diseases with tradipitant Download PDF

Info

Publication number
CA3081582A1
CA3081582A1 CA3081582A CA3081582A CA3081582A1 CA 3081582 A1 CA3081582 A1 CA 3081582A1 CA 3081582 A CA3081582 A CA 3081582A CA 3081582 A CA3081582 A CA 3081582A CA 3081582 A1 CA3081582 A1 CA 3081582A1
Authority
CA
Canada
Prior art keywords
tradipitant
gastroparesis
day
disease
responsive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3081582A
Other languages
English (en)
French (fr)
Inventor
Mihael H. Polymeropoulos
Gunther Birznieks
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanda Pharmaceuticals Inc
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of CA3081582A1 publication Critical patent/CA3081582A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3081582A 2017-11-17 2018-11-16 Method of treatment of gastrointestinal diseases with tradipitant Pending CA3081582A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762587681P 2017-11-17 2017-11-17
US62/587,681 2017-11-17
PCT/US2018/061593 WO2019099883A1 (en) 2017-11-17 2018-11-16 Method of treatment of gastrointestinal diseases with tradipitant

Publications (1)

Publication Number Publication Date
CA3081582A1 true CA3081582A1 (en) 2019-05-23

Family

ID=64734107

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3081582A Pending CA3081582A1 (en) 2017-11-17 2018-11-16 Method of treatment of gastrointestinal diseases with tradipitant

Country Status (19)

Country Link
US (4) US20200030307A1 (enExample)
EP (1) EP3710000B1 (enExample)
JP (1) JP7306614B2 (enExample)
KR (2) KR102864285B1 (enExample)
CN (2) CN119074729A (enExample)
AU (1) AU2018367623B2 (enExample)
BR (1) BR112020009520A2 (enExample)
CA (1) CA3081582A1 (enExample)
CL (1) CL2020001290A1 (enExample)
DK (1) DK3710000T3 (enExample)
ES (1) ES3032138T3 (enExample)
FI (1) FI3710000T3 (enExample)
HR (1) HRP20250615T1 (enExample)
HU (1) HUE071527T2 (enExample)
IL (1) IL274541B2 (enExample)
MX (1) MX2020005167A (enExample)
PT (1) PT3710000T (enExample)
SI (1) SI3710000T1 (enExample)
WO (1) WO2019099883A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016141341A1 (en) * 2015-03-04 2016-09-09 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
US20210228555A1 (en) * 2018-06-08 2021-07-29 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
CN111918701B (zh) * 2018-09-28 2024-08-02 万达制药公司 曲地匹坦在晕动病中的用途
WO2020117811A1 (en) 2018-12-03 2020-06-11 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
JP7791832B2 (ja) 2020-03-26 2025-12-24 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによる下気道感染症の治療
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
JP2025542424A (ja) 2022-12-21 2025-12-25 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによる処置の方法
EP4599831A1 (en) 2024-02-09 2025-08-13 Vanda Pharmaceuticals Inc. Treatment of gastroparesis with tradipitant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003230829B8 (en) 2002-04-26 2008-12-11 Eli Lilly And Company Triazole derivatives as tachykinin receptor antagonists
KR100848407B1 (ko) * 2003-10-24 2008-07-28 일라이 릴리 앤드 캄파니 ｛2-[1-(3,5-비스-트리플루오로메틸벤질)-5-피리딘-4-일-1ｈ-[1,2,3]트리아졸-4-일]-피리딘-3-일｝-(2-클로로페닐)-메탄온의 신규 결정질 형태
WO2008079600A1 (en) * 2006-12-20 2008-07-03 Eli Lilly And Company Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
HRP20140759T1 (hr) * 2009-11-18 2014-10-24 Helsinn Healthcare S.A. Kompozicije za lijeäśenje središnje posredovane muäśnine i povraä†anja
WO2016141341A1 (en) * 2015-03-04 2016-09-09 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
CA3009325A1 (en) 2015-12-22 2017-06-29 Takeda Pharmaceutical Company Limited Tripartite modulators of endosomal g protein-coupled receptors

Also Published As

Publication number Publication date
JP2021503480A (ja) 2021-02-12
US20210330656A1 (en) 2021-10-28
AU2018367623A1 (en) 2020-05-21
US20200030307A1 (en) 2020-01-30
NZ764107A (en) 2024-07-05
EP3710000B1 (en) 2025-04-23
CN111343981A (zh) 2020-06-26
IL274541B1 (en) 2024-06-01
US20210093621A1 (en) 2021-04-01
SI3710000T1 (sl) 2025-07-31
KR20200088346A (ko) 2020-07-22
WO2019099883A1 (en) 2019-05-23
PT3710000T (pt) 2025-05-29
FI3710000T3 (fi) 2025-07-03
RU2020119259A (ru) 2021-12-17
AU2018367623B2 (en) 2024-03-28
CN119074729A (zh) 2024-12-06
CL2020001290A1 (es) 2020-11-13
KR102864285B1 (ko) 2025-09-24
IL274541B2 (en) 2024-10-01
EP3710000A1 (en) 2020-09-23
JP7306614B2 (ja) 2023-07-11
KR20250140655A (ko) 2025-09-25
BR112020009520A2 (pt) 2020-11-03
HUE071527T2 (hu) 2025-09-28
MX2020005167A (es) 2020-08-20
HRP20250615T1 (hr) 2025-07-18
US20230390269A1 (en) 2023-12-07
DK3710000T3 (da) 2025-06-16
ES3032138T3 (en) 2025-07-15
IL274541A (en) 2020-06-30

Similar Documents

Publication Publication Date Title
US20230390269A1 (en) Method of treatment with tradipitant
De Ponti Pharmacology of serotonin: what a clinician should know
US20220096449A1 (en) Method of treatment with tradipitant
US20240285588A1 (en) Use of tradipitant in motion sickness
US20210008037A1 (en) Use of tradipitant in motion sickness
EA018927B1 (ru) Способ лечения когнитивного расстройства, ассоциированного с шизофренией
Prommer Aprepitant (EMEND) the role of substance P in nausea and vomiting
RU2797248C2 (ru) Способ лечения заболеваний желудочно-кишечного тракта традипитантом
TW202131921A (zh) Cxcr7拮抗劑與s1p1受體調節劑之組合
US20240299373A1 (en) Improved use of tradipitant in motion sickness
CN1247578C (zh) 含有2－芳基－8－氧化二氢嘌呤衍生物作为活性成分的痴呆症治疗剂
NZ766397B2 (en) Use of tradipitant in motion sickness

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231114

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241105

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241108

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241108

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241108

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250219

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250219

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250603

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250603